Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed non-small cell lung carcinoma (NSCLC) meeting the following criteria:

  * The following subtypes are eligible:

    * Adenocarcinoma (including bronchoalveolar)
    * Large cell carcinoma (including giant and clear cell carcinomas)
    * Poorly differentiated carcinoma
  * No squamous cell histology
  * Unresectable stage II-III disease
  * Tumor must not invade the trachea or major arterial or venous structures
* Measurable or evaluable disease

  * Measurable disease defined as ? 1 lesion that can be accurately measured in ? 1 dimension as ? 20 mm with conventional techniques or as ? 10 mm with spiral CT scan
* No evidence of CNS disease, including primary brain tumor or brain metastases
* ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%
* Life expectancy \> 6 months
* Granulocyte count ? 1,500/mm³
* Platelet count ? 100,000/mm³
* Bilirubin \< 1.25 times upper limit of normal (ULN)
* AST \< 2.5 times ULN
* Creatinine normalOR creatinine clearance ? 60 mL/min
* FEV\_1 ? 1.0 liters
* 24-hour urine protein \< 1,000 mg (for patients with urine protein:creatinine ratio \[by urine analysis\] \> 1.0)
* No hemoptysis within the past 12 months (defined as bright red blood in sputum of \> 1 teaspoon)
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
* No history of allergic reactions attributed to carboplatin or taxane
* No serious or nonhealing wound, ulcer, or bone fracture
* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
* No significant traumatic injury within the past 14 days
* No clinically significant cardiovascular disease, including any of the following:

  * Cerebrovascular accident within the past 6 months
  * Uncontrolled hypertension
  * Myocardial infarction or unstable angina within the past 6 months
  * New York Heart Association class II-IV congestive heart failure
  * Serious cardiac arrhythmia requiring medication
  * Unstable angina pectoris
  * Clinically significant peripheral vascular disease
* No known bleeding diathesis or coagulopathy
* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
* No uncontrolled intercurrent illness including, but not limited to, the following:

  * Ongoing or active infection
  * Psychiatric illness or social situations that would limit study compliance
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ? 6 months after completion of study treatment
* No HIV positivity
* No prior chemotherapy
* No prior epidermal growth factor receptor-targeted therapy
* No prior vascular endothelial growth factor-targeted therapy
* No prior chest radiotherapy
* No major surgery or open biopsy within the past 14 days
* No concurrent treatment with full-dose anticoagulation

  * Low-dose anticoagulants (e.g., warfarin) to maintain patency of central venous catheter allowed provided all of the following criteria are met:

    * Daily dose of warfarin \< 1 mg
    * INR \< 1.5
* No other concurrent investigational agents
* No concurrent major surgical procedures
* No other concurrent anticancer agents or therapies
* No concurrent chronic treatment with aspirin (\> 325 mg daily) or nonsteroidal anti-inflammatory agents
* No dexamethasone as an antiemetic during chemoradiotherapy
* No colony-stimulating factors during chemoradiotherapy